BioNTech Reports Phase 2 Pumitamig Data in Advanced NSCLC
Pumitamig plus docetaxel produced a 36.7% confirmed ORR among 30 evaluable patients and median PFS of 6.9 months among 50 treated, with manageable safety.
BioNTech reported first global Phase 2 data for pumitamig plus docetaxel in advanced NSCLC after IO+chemo, showing 36.7% confirmed ORR in 30 evaluable patients and median PFS of 6.9 months in 50 treated, with manageable safety.Material DetailsContext by AI AnalystThis is mid-stage efficacy/safety r…